Publications
A list of publications related with our COST Action
This is a collection of Publications related to our COST Action
Development of a Machine-Learning Model for Diagnosis of Pancreatic Cancer from Serum Samples Analyzed by Thermal Liquid Biopsy
Sonia Hermoso-Durán, Nicolas Fraunhoffer, Judith Millastre-Bocos, Oscar Sanchez-Gracia, Pablo F. Garrido, Sonia Vega, Ángel Lanas, Juan Iovanna, Adrián Velázquez-Campoy,* and Olga Abian*
Pancreatic ductal adenocarcinoma (PDAC) poses a considerable diagnostic and therapeutic challenge due to the lack of specific biomarkers and late diagnosis. Early detection is crucial for improving prognosis, but current techniques are insufficient. An innovative approach based on differential scanning calorimetry (DSC) of blood serum samples, thermal liquid biopsy (TLB), combined with machine-learning (ML) analysis, may offer a more efficient method for diagnosing PDAC. Serum samples from a cohort of 212 PDAC patients and 184 healthy controls are studied. DSC thermograms are analyzed using ML models. The generated models are built applying algorithms based on penalized regression, resampling, categorization, cross validation, and variable selection. The MLbased model demonstrates outstanding ability to discriminate between PDAC patients and control subjects, with a sensitivity of 90% and an area under the ROC receiver operating characteristic curve of 0.83 in the training and test groups. Application of the model to an independent validation cohort of 113 PDAC patients confirms its robustness and utility as a diagnosis tool. The application of ML to serum TLB data emerges as a promising methodology for early diagnosis, representing a significant advance for detecting and managing PDAC, envisaging a minimally invasive and more efficient methodology for identifying biomarkers.
The PANcreatic Disease ReseArch (PANDoRA) consortium turns 10! A summary of their main findings can be found in this anniversary paper
The PANcreatic Disease ReseArch (PANDoRA) consortium turns 10! A summary of their main findings can be found in this anniversary paper -> https://doi.org/10.1016/j.critrevonc.2023.104020
Pancreatic disease research (PANDoRA) is dedicated to the identification of pancreatic cancer risk loci and is the largest such consortium in Europe. PANDoRA is spread across 12 European countries, Brazil and Japan, bringing together 29 basic and clinical research groups. In the last ten years, PANDoRA has contributed to the discovery of 25 susceptibility loci, a feat that will be instrumental in stratifying the population by risk and optimizing preventive strategies.
Fibroblasts in pancreatic cancer: molecular and clinical perspectives
Rebelo R, Xavier CPR, Giovannetti E, Vasconcelos MH.
Trends Mol Med. 2023 Jun;29(6):439-453. doi: 10.1016/j.molmed.2023.03.002. Epub 2023 Apr 24.
PMID: 37100646
Exploring the Neandertal legacy of pancreatic ductal adenocarcinoma risk in Eurasians
Piccardi M, Gentiluomo M, Bertoncini S, Pezzilli R, Erőss B, Bunduc S, Uzunoglu FG, Talar-Wojnarowska R, Vanagas T, Sperti C, Oliverius M, Aoki MN, Ermini S, Hussein T, Boggi U, Jamroziak K, Maiello E, Morelli L, Vodickova L, Di Franco G, Landi S, Szentesi A, Lovecek M, Puzzono M, Tavano F, van Laarhoven HWM, Zerbi A, Mohelnikova-Duchonova B, Stocker H, Costello E, Capurso G, Ginocchi L, Lawlor RT, Vanella G, Bazzocchi F, Izbicki JR, Latiano A, Bueno-de-Mesquita B, Ponz de Leon Pisani R, Schöttker B, Soucek P, Hegyi P, Gazouli M, Hackert T, Kupcinskas J, Poskiene L, Tacelli M, Roth S, Carrara S, Perri F, Hlavac V, Theodoropoulos GE, Busch OR, Mambrini A, van Eijck CHJ, Arcidiacono P, Scarpa A, Pasquali C, Basso D, Lucchesi M, Milanetto AC, Neoptolemos JP, Cavestro GM, Janciauskas D, Chen X, Chammas R, Goetz M, Brenner H, Archibugi L, Dannemann M, Canzian F, Tofanelli S, Campa D.
Biol Res. 2023 Aug 13;56(1):46. doi: 10.1186/s40659-023-00457-y.
PMID: 37574541
Nanomedicine and epigenetics: New alliances to increase the odds in pancreatic cancer survival
Urbanova M, Cihova M, Buocikova V, Slopovsky J, Dubovan P, Pindak D, Tomas M, García-Bermejo L, Rodríguez-Garrote M, Earl J, Kohl Y, Kataki A, Dusinska M, Sainz B Jr, Smolkova B, Gabelova A.
Biomed Pharmacother. 2023 Sep;165:115179. doi: 10.1016/j.biopha.2023.115179. Epub 2023 Jul 21.
PMID: 37481927
Analysis of exposome and genetic variability suggests stress as a major contributor for development of pancreatic ductal adenocarcinoma.
Peduzzi G, Felici A, Pellungrini R, Giorgolo F, Farinella R, Gentiluomo M, Spinelli A, Capurso G, Monreale A, Canzian F, Calderisi M, Campa D.
Dig Liver Dis. 2023 Nov 18:S1590-8658(23)01004-6. doi: 10.1016/j.dld.2023.10.015. Online ahead of print.
PMID: 37985251
Thinking small to win big? A critical review on the potential application of extracellular vesicles for biomarker discovery and new therapeutic approaches in pancreatic cancer
Vahabi M, Comandatore A, Centra C, Blandino G, Morelli L, Giovannetti E.
Semin Cancer Biol. 2023 Dec;97:50-67. doi: 10.1016/j.semcancer.2023.11.003. Epub 2023 Nov 11.
PMID: 37956937
Polymorphisms in transcription factor binding sites and enhancer regions and pancreatic ductal adenocarcinoma risk
Ünal P, Lu Y, Bueno-de-Mesquita B, van Eijck CHJ, Talar-Wojnarowska R, Szentesi A, Gazouli M, Kreivenaite E, Tavano F, Małecka-Wojciesko E, Erőss B, Oliverius M, Bunduc S, Nóbrega Aoki M, Vodickova L, Boggi U, Giaccherini M, Kondrackiene J, Chammas R, Palmieri O, Theodoropoulos GE, Bijlsma MF, Basso D, Mohelnikova-Duchonova B, Soucek P, Izbicki JR, Kiudelis V, Vanella G, Arcidiacono PG, Włodarczyk B, Hackert T, Schöttker B, Uzunoglu FG, Bambi F, Goetz M, Hlavac V, Brenner H, Perri F, Carrara S, Landi S, Hegyi P, Dijk F, Maiello E, Capretti G, Testoni SGG, Petrone MC, Stocker H, Ermini S, Archibugi L, Gentiluomo M, Cavestro GM, Pezzilli R, Di Franco G, Milanetto AC, Sperti C, Neoptolemos JP, Morelli L, Vokacova K, Pasquali C, Lawlor RT, Bazzocchi F, Kupcinskas J, Capurso G, Campa D, Canzian F.
Hum Genomics. 2024 Feb 2;18(1):12. doi: 10.1186/s40246-024-00576-x.
PMID: 38308339
Treatment resistance in pancreatic and biliary tract cancer: molecular and clinical pharmacology perspectives
Toledo B, Deiana C, Scianò F, Brandi G, Marchal JA, Perán M, Giovannetti E.
Expert Rev Clin Pharmacol. 2024 Mar 15:1-25. doi: 10.1080/17512433.2024.2319340. Online ahead of print.
PMID: 38413373
Spliceosomic dysregulation in pancreatic cancer uncovers splicing factors PRPF8 and RBMX as novel candidate actionable targets
Alors-Pérez E, Blázquez-Encinas R, Moreno-Montilla MT, García-Vioque V, Jiménez-Vacas JM, Mafficini A, González-Borja I, Luchini C, Sánchez-Hidalgo JM, Sánchez-Frías ME, Pedraza-Arevalo S, Romero-Ruiz A, Lawlor RT, Viúdez A, Gahete MD, Scarpa A, Arjona-Sánchez Á, Luque RM, Ibáñez-Costa A, Castaño JP
Mol Oncol. 2024 May 24. doi: 10.1002/1878-0261.13658. Epub ahead of print
PMID: 38790138
Splicing alterations in pancreatic ductal adenocarcinoma: a new molecular landscape with translational potential
Alors-Pérez E, Pedraza-Arevalo S, Blázquez-Encinas R, Moreno-Montilla MT, García-Vioque V, Berbel I, Luque RM, Sainz B Jr, Ibáñez-Costa A, Castaño JP
J Exp Clin Cancer Res. 2023 Oct 26;42(1):282. doi: 10.1186/s13046-023-02858-z
PMID: 37880792
PMCID: PMC10601233